In our analysis, before applying the Bonferroni correction, serum MMP-3 levels were associated with an increased risk of DVT (OR, 1.05; 95% CI, 1.01 to 1.09; p= 0.012) and a decreased risk of PE (OR, 0.95; 95% CI, 0.92 to 0.99; p= 0.006). The gene discussed is MMP3; the disease is deep vein thrombosis.